Mr. Steve Saviuk reports
VALEO PHARMA INC. ENTERS INTO AN AGREEMENT FOR ENERZAIR BREEZHALER AND ATECTURA BREEZHALER IN CANADA
Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF) (FSE: VP2) ("Valeo" or the "Company") has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two asthma therapies, Enerzair Breezhaler (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura Breezhaler (indacaterol (as acetate) and mometasone furoate).
Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzairtrademark Breezhalertrademark and Atecturatrademark Breezhalertrademark for ...
Read The Full Article On StockStreetNews.com
Get early insight on hidden secret gems on StockStreetNews . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by StockStreetNews is subject to our Terms Of Use and Disclaimer .
For further details see:
Valeo To Commercialize Novartis Asthma Therapies